Literature DB >> 27658846

The replicability of cannabis use prevalence estimates in the United States.

Omayma Alshaarawy1,2, James C Anthony2.   

Abstract

Recent changes in cannabis policy in the United States have prompted increased interest in cannabis use estimates, and replicability of these estimates. Here, we compare prevalence estimates from two concurrent approaches: (1) standard social survey with audio computer-assisted self-interviews at respondent's home (ACASI-H), derived from the National Surveys on Drug Use and Health (NSDUH), and (2) standard health survey with ACASI assessment in a mobile health examination vehicle (ACASI-M), derived from National Health and Nutrition Examination Surveys (NHANES), 2005-2012, with essentially the same standardized items in cannabis modules. NHANES ACASI-M prevalence proportions for recently-active-cannabis-use are an estimated 130-140% larger than corresponding NSDUH ACASI-H estimates (p < 0.05). In exploratory stratified analyses, we sought to understand these NHANES-NSDUH differences, and found no differences in lifetime-history-of-cannabis-use. However, for participants living with others in the same residence, moving cannabis assessment out of the dwelling unit might promote larger recently-active-cannabis-use estimates; no NHANES-NSDUH differences were found for participants living alone. The observed discrepancies might be non-ignorable in a policy or program evaluation context. A methods research program will be needed to account for between-survey differences of the type observed here, perhaps with a focus on within-residence versus non-residence assessment as a source of variation.
Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  NHANES; NSDUH; cannabis; prevalence; survey

Mesh:

Year:  2016        PMID: 27658846      PMCID: PMC5364066          DOI: 10.1002/mpr.1524

Source DB:  PubMed          Journal:  Int J Methods Psychiatr Res        ISSN: 1049-8931            Impact factor:   4.035


  6 in total

1.  Discrepancies in prevalence estimates in two national surveys for nonmedical use of a specific opioid product versus any prescription pain reliever.

Authors:  Gabriella Biondo; Howard D Chilcoat
Journal:  Drug Alcohol Depend       Date:  2013-10-24       Impact factor: 4.492

2.  Influence of privacy on self-reported drug use by youths.

Authors:  J Gfroerer
Journal:  NIDA Res Monogr       Date:  1985

3.  Discrepancies in estimates of prevalence and correlates of substance use and disorders between two national surveys.

Authors:  Richard A Grucza; Anna M Abbacchi; Thomas R Przybeck; Joseph C Gfroerer
Journal:  Addiction       Date:  2007-02-15       Impact factor: 6.526

4.  The replicability of cannabis use prevalence estimates in the United States.

Authors:  Omayma Alshaarawy; James C Anthony
Journal:  Int J Methods Psychiatr Res       Date:  2016-09-23       Impact factor: 4.035

5.  Prevalence, correlates, disability, and comorbidity of DSM-IV borderline personality disorder: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Bridget F Grant; S Patricia Chou; Risë B Goldstein; Boji Huang; Frederick S Stinson; Tulshi D Saha; Sharon M Smith; Deborah A Dawson; Attila J Pulay; Roger P Pickering; W June Ruan
Journal:  J Clin Psychiatry       Date:  2008-04       Impact factor: 4.384

6.  Design and results of the Women's Health Study.

Authors:  R Tourangeau; J B Jobe; W F Pratt; K Rasinski
Journal:  NIDA Res Monogr       Date:  1997
  6 in total
  3 in total

1.  Cannabis use among women of reproductive age in the United States: 2002-2017.

Authors:  Omayma Alshaarawy; James C Anthony
Journal:  Addict Behav       Date:  2019-08-07       Impact factor: 3.913

2.  The replicability of cannabis use prevalence estimates in the United States.

Authors:  Omayma Alshaarawy; James C Anthony
Journal:  Int J Methods Psychiatr Res       Date:  2016-09-23       Impact factor: 4.035

3.  Cannabis use among cancer survivors in the United States: Analysis of a nationally representative sample.

Authors:  Elizabeth K Do; Albert J Ksinan; Sunny Jung Kim; Egidio G Del Fabbro; Bernard F Fuemmeler
Journal:  Cancer       Date:  2021-07-20       Impact factor: 6.860

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.